Evidence map›Paper›PMID 29861171›Full record

ArticleCell host & microbe2018

Functional Relevance of Improbable Antibody Mutations for HIV Broadly Neutralizing Antibody Development.

Kevin Wiehe, Todd Bradley, R Ryan Meyerhoff, Connor Hart, Wilton B Williams, David Easterhoff, William J Faison, Thomas B Kepler, Kevin O Saunders, S Munir Alam and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Cell host & microbe, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 100 papers.

0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
7.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

100 citing papers in PubMed, 140 citations in OpenAlex.

  1. Priming of Multiple HIV Neutralizing B Cell Precursors in Humans.medRxiv : the preprint server for health sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Clonal dynamics of germinal center refueling by secondary immunization.bioRxiv : the preprint server for biology · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

40 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Kevin WieheDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA. Electronic address: kevin.wiehe@duke.edu.
Todd BradleyDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA.
R Ryan MeyerhoffDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Immunology, Duke University School of Medicine, Durham, NC 22710, USA.
Connor HartDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Wilton B WilliamsDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA.
David EasterhoffDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA.
William J FaisonDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.
Thomas B KeplerDepartment of Microbiology, Boston University School of Medicine, Boston, MA 02215, USA; Department of Mathematics and Statistics, Boston Univeristy, Boston, MA 02215, USA.
Kevin O SaundersDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
S Munir AlamDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
Mattia BonsignoriDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA.
Barton F HaynesDuke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA; Department of Medicine, Duke University School of Medicine, Durham, NC 22710, USA. Electronic address: barton.haynes@duke.edu.
Duke University · USBoston University · US

Funding

Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Translational ScienceP30AI042853 · NIAID · MIRIAM HOSPITAL · PI LARRY K BROWN · 1998 to 2026
$51.7M
Social and Behavioral Sciences CoreP30AI064518 · NIAID · DUKE UNIVERSITY · PI Nwora Lance Okeke · 2005 to 2026
$50.5M
Virus and Antibody Gene Sequencing CoreP01AI131251 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI GEORGE M SHAW · 2017 to 2026
$40.7M
MEDICAL SCIENTIST TRAINING PROGRAMT32GM007171 · NIGMS · DUKE UNIVERSITY · PI KONTOS, CHRISTOPHER D · 1985 to 2021
$31.2M
Ruth L. Kirschstein National Research Service Award (NRSA)- T32T32AI007392 · NIAID · DUKE UNIVERSITY · PI Amy Lynn Corneli, Guido Ferrari · 1990 to 2026
$9.8M
Data commons for 'omic, microscopy and analysis core facilitiesS10OD018164 · OD · DUKE UNIVERSITY · PI WRAY, GREGORY A. · 2014 to 2014
$598k
Novel mouse model of HIV broad neutralizing antibody inductionF30AI122982 · NIAID · DUKE UNIVERSITY · PI MEYERHOFF, ROBERT RYAN · 2016 to 2017
$79k
NIAID NIH HHS F30 AI122982NIAID NIH HHS P01 AI131251NIAID NIH HHS P30 AI042853NIAID NIH HHS P30 AI064518NIAID NIH HHS T32 AI007392NIAID NIH HHS UM1 AI100645NIGMS NIH HHS T32 GM007171NIH HHS S10 OD018164
6 · The paper itself

Abstract

HIV-1 broadly neutralizing antibodies (bnAbs) require high levels of activation-induced cytidine deaminase (AID)-catalyzed somatic mutations for optimal neutralization potency. Probable mutations occur at sites of frequent AID activity, while improbable mutations occur where AID activity is infrequent. One bottleneck for induction of bnAbs is the evolution of viral envelopes (Envs) that can select bnAb B cell receptors (BCR) with improbable mutations. Here we define the probability of bnAb mutations and demonstrate the functional significance of key improbable mutations in three bnAb B cell lineages. We show that bnAbs are enriched for improbable mutations, which implies that their elicitation will be critical for successful vaccine induction of potent bnAb B cell lineages. We discuss a mutation-guided vaccine strategy for identification of Envs that can select B cells with BCRs that have key improbable mutations required for bnAb development.

Indexed as

MutationAICDA (Activation-Induced Cytidine Deaminase)AIDS VaccinesAntibodies, NeutralizingB-LymphocytesCytidine DeaminaseHIV-1HIV AntibodiesHIV InfectionsHumansMutation RateProbabilityViral Envelope ProteinsAICDA (Activation-Induced Cytidine Deaminase)AIDS VaccinesAntibodies, NeutralizingCytidine DeaminaseHIV AntibodiesViral Envelope Proteins

Identifiers

PMID29861171
PMCPMC6002614
OpenAlexW2805330890

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.